According to experts, genomic testing is a key tool impacting treatment decisions for physicians treating patients with non–small cell lung cancer.
Conor Killmurray
Conor Killmurray is an editor for Targeted Oncology and Peers and Perspectives in Oncology.
Articles by Conor Killmurray
Utilizing the combination of inotuzuamb ozogamicin and low intensity chemotherapy, with or without blinatumoamab, showed promising results, but also an increase of patient deaths during remission.
In a comparison of 2 live events from the Targeted Oncology Case-Based Roundtable series, we look at how adding daratumumab to therapy for patients with newly diagnosed disease who cannot receive a transplant has shifted the approach to treatment.
In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the initial results of the addition of acalabrutinib to bendamustine and rituximab to treat patients with mantle cell lymphoma.
Discussing findings from a phase 1/2 study, Sarah P. Psutka MD, looks at the use of acupuncture for patients with non muscle-invasive bladder cancer prior to induction of their BCG treatment.
In an interview with Targeted Oncology, Jorge Cortes, MD, highlights the use of olutasidenib in patients with relapsed/refractory acute myeloid leukemia.
Data from a phase 1 dose escalation study showed tolerability and antitumor activity with IBI351 in patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.
The addition of acalabrutinib to bendamustine and rituximab met tolerability and safety end points in a phase 1b trial, as well as promising efficacy results in patients with either treatment-naive or relapsed/refractory mantle cell lymphoma.
New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.
Results from the TALAPRO-2 study highlight the potential for the first-line treatment of patients with homologous recombination repair altered metastatic castration-resistant prostate cancer.
Results from the phase 2 MAJIC-PV study showed that patients with polycythemia vera who are intolerant to hydroxycarbamide chemotherapy had superior efficacy results on ruxolitinib.
For Bladder Cancer Awareness Month, Jahan Aghalar, MD, discussed the latest advancements in treating patients with bladder cancer along with which targets have helped to push the field forward.
The FDA approved the use of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma.
For Brain Cancer Awareness Month, Charles Redfern, MD, discussed the biggest technological changes to treatment for adult patients with brain cancer and how holistic treatment remains important for treating this challenging disease.
In an interview with Targeted Oncology, Petros Grivas, MD, PhD, discusses the set up and key results from the KEYNOTE-057 trial of pembrolizumab for patients with bacillus Calmette-Guérin-unresponsive, papillary high-risk non–muscle-invasive bladder cancer.
An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.
Looking at real-world data, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.
For Head and Neck Cancer Awareness Month, we looked at the connection between the human papillomavirus and this disease, and the role it has in determining treatment now and in the future.
Primary end point data from the phase 2 KEYNOTE-695 study did not meet the prespecified end point of overall response rate for patients with advanced melanoma.
At the 2023 National Comprehensive Cancer Network Annual Conference, Arlene O. Siefker-Radtke, MD, gave an assessment on where emerging targeted therapies for patients with metastatic or advanced bladder stand.
Updated results from the phase 1 study of the bioavailable KRAS G12C inhibitor IBI351 showed that monotherapy was tolerable with promising activity in patients with advanced non–small cell lung cancer whose tumor harbored the KRAS G12C mutation.
A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small cell lung cancer treated with cemiplimab.
New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.
In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.
Multiple Myeloma expert Santhosh K Sadavish MD, discusses the importance of targeted therapies for these patients and how CAR T-cell therapy has changed the outcomes of patients who relapse after multiple lines of therapy.
In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.
The FDA has granted the cell therapy temferon an orphan drug designation to treat patients with brain cancer.
Miguel Pelayo, MD, discusses what he sees as practice-changing treatments for patients with triple-negative breast cancer and how he helps patients feel confident in these new treatments.
In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.
Discussing his presentation from the 2023 ASCO Genitourinary Symposium, Neal Shore, MD, FACS, looks at the long-term results of the phase 3 ARAMIS study for patients with nonmetastatic castration-resistant prostate cancer on darolutamide.